□ 周 好 非物质文化遗产（以下简称"非遗"）作为特定地域内世代相传的文化遗产，承载着当地的历史文化、社 群技艺、审美观念和价值取向，是中华优秀传统文化的精粹所在，也是推进实现文化强国建设、弘扬和 践行社会主义核心价值观的重要载体。伴随着城市化进程的加快，非遗传承面临着原生场景变迁、地域 发展失衡、传承队伍断层等现实困境，以数智化手段重构非遗表达与传承模式，为地方非遗传承开辟了 新路径。 依托知识图谱构建，牢固非遗地域保护根基 数智化知识图谱的构建，是助力非遗区域性整体保护，实现从零散记录到系统保护跃升的关键路径。大 数据技术能够将地方非遗的代表性项目、代表性传承人、技艺方法等显性要素进行结构整合，同时对审 美倾向、民俗禁忌等隐性要素进行语义关联，形成可视化的文化基因图谱，全面了解地方文化发展脉 络，并可基于此构建准确权威、开放共享的地方非遗数字平台，彻底突破传统"档案化保存"的静态模 式，转变为可关联、可交互的非遗动态保护新形式。 非遗作为一种民间文化，具有强烈的地域代表性，其独特的文化特质来源于该地区的自然生态、生活方 式、民俗习惯、方言系统等，以区域性整体保护为策略，更有利于地区文化的存续和认同。如非遗 ...

Summary of the Conference Call on Hualan's AI Pharmaceutical Developments Company and Industry Overview - **Company**: Hualan Co., Ltd. (华兰股份) - **Industry**: AI Pharmaceutical Development - **Context**: The conference call was organized by Tianfeng Securities and several other brokerages to discuss Hualan's recent developments in the AI pharmaceutical sector, particularly its collaboration with various experts and companies in the field [1][2]. Key Points and Arguments Hualan's Background and Business Model - Hualan has over 30 years of experience and was listed in 2021, primarily known for its medical rubber products [3]. - The company has a stable revenue and profit stream, with a strong customer base of over 1,000 pharmaceutical companies, many of which have long-term relationships spanning 20-30 years [4]. - Hualan has completed capacity construction for new products and has a solid cash flow, which supports its entry into AI pharmaceuticals [5]. AI Pharmaceutical Strategy - Hualan's strategy involves leveraging its extensive customer base to support AI pharmaceutical initiatives, aiming to reduce time and costs for technology teams to connect with clients [6]. - The company plans to open its customer resource pool to all teams joining Hualan, enhancing collaboration and trust with clients [6]. Internal and External Development - Hualan has established an expert committee to guide its AI pharmaceutical direction, focusing on internal incubation and external investments [9][10]. - The company is developing four main areas: knowledge graph, small molecules, antibodies, and small nucleic acids, with a focus on mature and validated technologies [10]. Collaboration with Kema Bio - Hualan has invested in Kema Bio, which focuses on antibody design and optimization, emphasizing the importance of data accumulation and model optimization for effective drug development [12][13]. - Kema Bio's approach is to optimize models for specific targets, such as GPCRs, and to enhance the specificity and efficacy of antibodies [13][16]. Knowledge Graph Development - Hualan's knowledge graph initiative aims to structure and visualize relationships between various biological entities, enhancing drug repurposing and safety monitoring [19][20]. - The knowledge graph will facilitate the identification of new indications for existing drugs, potentially shortening development timelines [22][23]. Future Goals and Market Positioning - Hualan aims to position its AI pharmaceutical business on par with its core rubber product business, with a goal to exceed current performance levels within 3-5 years [43][44]. - The company is focused on integrating AI capabilities with existing operations to enhance service offerings and customer engagement [44]. Additional Important Content - The conference highlighted the importance of collaboration with top-tier experts and the establishment of a robust technological foundation for future developments [9][10]. - Hualan's commitment to maintaining high standards in its AI pharmaceutical initiatives was emphasized, with specific performance milestones set for the knowledge graph team [46]. - The call also addressed the competitive landscape and the need for high-quality knowledge graphs to gain market acceptance [33][34]. This summary encapsulates the key discussions and strategic directions outlined during the conference call, reflecting Hualan's ambitions in the AI pharmaceutical sector and its operational synergies.

格隆汇2月9日丨华兰股份(301093.SZ)公布，董事会同意公司全资子公司海南灵擎数智医药科技有限公 司（在本公告里简称"灵擎数智"）与美国Insilicom LLC前首席技术官俞开先先生（CTO）及美国科学院 院士LIU JUN（刘军）先生领衔的技术团队开展合作，即灵擎数智、持股平台1（将由灵擎数智与俞开 先所控制的公司共同出资设立）、持股平台2【将由俞开先所控制的公司与LIU JUN（刘军）共同出资 设立】拟以自有资金共同出资设立一家合资公司。其中，灵擎数智控股合资公司，合资公司将纳入公司 合并报表范围。 合资公司拟聚焦于以知识图谱为核心的药物重定向与药物警戒相关服务，通过整合多源异构数据，为药 物研发与安全管理提供智能化解决方案，具体经营范围以工商登记信息为准。 ...

华兰股份公告，全资子公司海南灵擎数智医药科技有限公司拟与美国Insilicom LLC前首席技术官俞开先 及美国科学院院士LIU JUN（刘军）领衔的技术团队共同出资设立合资公司，其中灵擎数智出资600万 元，持股60%。合资公司聚焦以知识图谱为核心的药物重定向与药物警戒相关服务，旨在探索 人工智 能技术在医药研发与药物安全管理领域的应用场景。 ...

Group 1 - China People's Insurance Group (China P&C) is committed to enhancing service efficiency through technological innovation, focusing on the development of an intelligent Q&A system for medical insurance knowledge to meet the growing demand for medical insurance inquiries [1][2] - The project aims to build a high-efficiency and precise medical insurance knowledge intelligent Q&A system, with a tender announcement published on January 4, 2026, attracting several well-known technology companies to participate [1] - The procurement focuses on system development and knowledge base construction, utilizing intelligent Q&A technology to help China P&C quickly respond to medical insurance policy inquiries, reduce labor costs, and improve user experience [1] Group 2 - Cloud Wisdom Technology Co., Ltd. (Cloud Wisdom) successfully won the bid for the medical insurance knowledge intelligent Q&A system project from China P&C, with a bid amount of 2.714 million yuan [2] - This collaboration marks a significant breakthrough for Cloud Wisdom in the application of artificial intelligence within the insurance industry, providing core support for the intelligentization of medical insurance services at China P&C [2] - Cloud Wisdom's strong capabilities in natural language processing and knowledge graph technology were recognized by evaluation experts, leading to its top position in the list of winning candidates [1][2]

根据弗若斯特沙利文的数据，按2024年营业收入计，本公司在中国产业级AI智能体提供商中位列第 五，市场份额为2.8%;并在中国以图为核心的AI智能体提供商中位列第一，市场份额约为50%。根据弗 若斯特沙利文的数据，公司是行业内中国首家通过知识图谱有效减少大模型幻觉的企业，此现象指人工 智能模型产出看似连贯合理却实为错误、荒谬或事实不准确的输出内容。一家能够在事实准确度、幻觉 率及复杂逻辑推理能力叁大维度构建核心竞争力与技术壁垒的企业，能成功缓解大语言模型的幻觉问 题;在事实准确度维度，其可确保输出事实具备高可靠性;在幻觉率维度，其输出内容中无法验证或经验 证属错误的占比较低;在复杂逻辑推理能力维度，模型在深度推演过程中产生逻辑断裂或捏造推理链等 幻觉现象的概率更低。凭借公司在多应用场景知识图谱构建领域的专长，及自多应用场景中积累的经 验，再加上由公司客户提供的受控且经过验证的数据集，本公司在减少AI系统中的幻觉方面实现突 破。此项技术突破使公司能够开发智能体，并为企业提供人工智能解决方案。通过融合大语言模型强大 的推理规划能力、知识图谱的精确性与可解释性，加之公司的专业知识及落地实施能力，本公司开发的 智能体 ...

Core Viewpoint - The company, Haizhi Technology Group, is set to launch an IPO from February 5 to February 10, 2026, offering 28.03 million H-shares globally, with a maximum price of HKD 28.0 per share, aiming to raise approximately HKD 648 million for various strategic initiatives [1][6]. Group 1: Company Overview - The company is a leading enterprise in China focused on developing Atlas graph solutions and industrial-grade AI solutions through graph-model fusion technology [2]. - The Atlas graph solution is one of the core products, enabling efficient integration, processing, and management of data from multiple sources [2]. Group 2: Market Position and Performance - According to Frost & Sullivan, the company ranks fifth among industrial-grade AI providers in China with a market share of 2.8%, and first among graph-centric AI providers with a market share of approximately 50% [3]. - The company's revenue grew from RMB 313 million in 2022 to RMB 503 million in 2024, representing a compound annual growth rate (CAGR) of 26.8% [3]. Group 3: Technological Advancements - The company has developed a breakthrough technology that effectively reduces the "hallucination" phenomenon in large language models, ensuring high reliability in output facts and low rates of unverifiable errors [3]. - The Atlas intelligent agent, launched in September 2023, enhances the reasoning capabilities of large language models in specific industry contexts [4]. Group 4: Strategic Focus and Investment - The company is focusing on parallel development of the Atlas graph solution and Atlas intelligent agent, which allows it to capture growth opportunities during different stages of digital transformation [5]. - The company has entered cornerstone investment agreements with several investors, agreeing to raise approximately USD 15 million under certain conditions [6]. Group 5: Use of Proceeds - The net proceeds from the global offering are planned to be allocated as follows: approximately 45% for R&D to enhance graph-model fusion technology, 20% for optimizing the Atlas intelligent agent, 15% for deepening customer collaboration, 10% for strategic investments, and 10% for working capital and general corporate purposes [6].

格隆汇2月5日丨海致科技集团(02706.HK)发布公告，公司拟全球发售2803.02万股H股，中国香港发售股 份280.32万股，国际发售股份2522.7万股(以上可予重新分配)；2026年2月5日至2月10日招股，预期定价 日为2月11日；发售价将为每股发售股份25.6-28.0港元，H股的每手买卖单位将为200股，招银国际、中 银国际及申万宏源香港为联席保荐人；预期H股将于2026年2月13日开始于联交所买卖。 公司是中国领先的企业，专注于通过图模融合技术开发Atlas图谱解决方案及产业级智能体并提供产业 级人工智能解决方案。知识图谱是一种图谱结构化数据模型，将资料呈现为相互连结实体、其关系与属 性的网络；而大语言模型则是通过自监督机器学习，在海量文本资料上训练而成的AI模型，用于执行 自然语言处理任务，例如语言生成。Atlas图谱解决方案是公司于往绩记录期间的核心产品之一。Atlas 图谱解决方案基于公司行业领先的图计算与数据分析能力构建，包含DMC数据智能平台、Atlas知识图 谱平台及AtlasGraph图数据库。该等解决方案使企业能够高效整合、处理及管理来自多个来源的数据， 构建及分析知识图谱， ...

北京海致科技集團股份有限公司 Beijing Haizhi Technology Group Co., Ltd. （於中華人民共和國註冊成立的股份有限公司） 股份代號 : 2706 全球發售 聯席保薦人、整體協調人、聯席全球協調人、 聯席賬簿管理人及聯席牽頭經辦人 重要提示 重要提示：閣下如對本招股章程的任何內容有任何疑問，應徵詢獨立專業意見。 Beijing Haizhi Technology Group Co., Ltd. 北京海致科技集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 全球發售 全球發售項下的發售股份數目 ： 28,030,200股H股 香港發售股份數目 ： 2,803,200股H股（可予重新分配） 國際發售股份數目 ： 25,227,000股H股（可予重新分配） 最高發售價 ： 每股H股28.0港元，另加1.0%的經紀 佣金，0.0027%證監會交易徵費、 0.00565%香港聯交所交易費 及0.00015%會財局交易徵費（須於申 請時以港元繳足，多繳款項可予退還） 面值 ： 每股H股人民幣0.1元 股份代號 ： 2706 聯席保薦人、整體協調人、聯席全球協調人、 聯席賬簿管 ...

中国移动通信集团有限公司，成立于1999年，位于北京市，是一家以从事电信、广播电视和卫星传输服 务为主的企业。企业注册资本30000000万人民币。通过天眼查大数据分析，中国移动通信集团有限公司 共对外投资了55家企业，参与招投标项目5000次，财产线索方面有商标信息2211条，专利信息5000条， 此外企业还拥有行政许可50个。 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 国家知识产权局信息显示，中移(苏州)软件技术有限公司、中国移动通信集团有限公司取得一项名 为"一种知识图谱构建方法、装置和存储介质"的专利，授权公告号CN115374222B，申请日期为2021年5 月。 天眼查资料显示，中移(苏州)软件技术有限公司，成立于2014年，位于苏州市，是一家以从事软件和信 息技术服务业为主的企业。企业注册资本317200万人民币。通过天眼查大数据分析，中移(苏州)软件技 术有限公司参与招投标项目5000次，财产线索方面有商标信息112条，专利信息2689条，此外企业还拥 有行政许可28个。 ...